title: Janus kinase inhibitors and allogeneic stem cell transplantation for myelofibrosis.
abstract: Myelofibrosis (MF) is a manifestation of several disorders of hematopoiesis, collectively referred to as myeloproliferative neoplasms. Allogeneic hematopoietic stem cell transplantation (ASCT) is the only therapy with proven curative potential. However, most patients with MF are in their 6th or 7th decade of life, and only some of these patients have been considered suitable transplantation candidates. The development of reduced-intensity conditioning regimens with limited toxicity has allowed clinicians to offer ASCT to a growing number of older patients. The availability of Janus Kinase (JAK) 1/2 inhibitors allows clinicians to provide symptom relief and improved quality of life for MF patients. These drugs may also affect the decision regarding, in particular, the timing of ASCT. Future studies need to address the role of JAK1/2 inhibitors in patients who are transplantation candidates and determine their role before and, possibly, after transplantation. The identification of indications for the use of JAK1/2 inhibitors in the context of transplantation may lead to new therapeutic strategies for patients with MF.
authors.affiliation: Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Vikas
authors.initials: V
authors.lastname: Gupta
authors.affiliation: Stanford University School of Medicine, Palo Alto, California.
authors.forename: Jason
authors.initials: J
authors.lastname: Gotlib
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
authors.forename: Jerald P
authors.initials: JP
authors.lastname: Radich
authors.affiliation: University Medical Center, Hamburg, Germany.
authors.forename: Nicolaus M
authors.initials: NM
authors.lastname: Kröger
authors.affiliation: University of Illinois College of Medicine at Chicago, Chicago, Illinois.
authors.forename: Damiano
authors.initials: D
authors.lastname: Rondelli
authors.affiliation: Leukemia Department, MD Anderson Cancer Center, Houston, Texas.
authors.forename: Srdan
authors.initials: S
authors.lastname: Verstovsek
authors.affiliation: Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Electronic address: blarson@fhcrc.org.
authors.forename: H Joachim
authors.initials: HJ
authors.lastname: Deeg
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006801:Humans; D053612:Janus Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D055728:Primary Myelofibrosis / Q000628:therapy*; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous / Q000379:methods*
chemical_list: D053612:Janus Kinases
keywords: Homologous; INCB018424; Janus Kinase 1; Primary myelofibrosis; Transplantation